NasdaqGS - Nasdaq Real Time Price USD
scPharmaceuticals Inc. (SCPH)
At close: October 18 at 4:00 PM EDT
After hours: October 18 at 5:45 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
24,048.0000
13,593.0000
--
--
--
Cost of Revenue
6,937.0000
3,811.0000
--
--
--
Gross Profit
17,111.0000
9,782.0000
--
--
--
Operating Expense
77,494.0000
65,178.0000
36,157.0000
25,823.0000
29,933.0000
Operating Income
-60,383.0000
-55,396.0000
-36,157.0000
-25,823.0000
-29,933.0000
Net Non Operating Interest Income Expense
-4,420.0000
-3,019.0000
-2,099.0000
-2,526.0000
-2,272.0000
Other Income Expense
4,159.0000
3,605.0000
1,418.0000
315.0000
-4.0000
Pretax Income
-60,644.0000
-54,810.0000
-36,838.0000
-28,034.0000
-32,209.0000
Net Income Common Stockholders
-60,644.0000
-54,810.0000
-36,838.0000
-28,034.0000
-32,209.0000
Diluted NI Available to Com Stockholders
-60,644.0000
-54,810.0000
-36,838.0000
-28,034.0000
-32,209.0000
Basic EPS
-1.56
-1.42
-1.30
-1.02
-1.31
Diluted EPS
-1.56
-1.42
-1.30
-1.02
-1.31
Basic Average Shares
38,873.3380
38,513.7470
28,358.5020
27,351.7300
24,568.8970
Diluted Average Shares
38,873.3380
38,513.7470
28,358.5020
27,351.7300
24,568.8970
Total Operating Income as Reported
-60,383.0000
-55,396.0000
-36,157.0000
-25,823.0000
-29,933.0000
Total Expenses
84,431.0000
68,989.0000
36,157.0000
25,823.0000
29,933.0000
Net Income from Continuing & Discontinued Operation
-60,644.0000
-54,810.0000
-36,838.0000
-28,034.0000
-32,209.0000
Normalized Income
-60,644.0000
-54,810.0000
-36,838.0000
-28,034.0000
-32,209.0000
Interest Income
3,967.0000
5,104.0000
1,203.0000
49.0000
315.0000
Interest Expense
8,387.0000
8,123.0000
3,302.0000
2,575.0000
2,587.0000
Net Interest Income
-4,420.0000
-3,019.0000
-2,099.0000
-2,526.0000
-2,272.0000
EBIT
-52,257.0000
-46,687.0000
-33,536.0000
-25,459.0000
-29,622.0000
EBITDA
-51,742.0000
-46,061.0000
-33,068.0000
-25,021.0000
-29,223.0000
Reconciled Cost of Revenue
6,937.0000
3,811.0000
--
--
--
Reconciled Depreciation
515.0000
626.0000
468.0000
438.0000
399.0000
Net Income from Continuing Operation Net Minority Interest
-60,644.0000
-54,810.0000
-36,838.0000
-28,034.0000
-32,209.0000
Normalized EBITDA
-51,742.0000
-46,061.0000
-33,068.0000
-25,021.0000
-29,223.0000
12/31/2020 - 11/17/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
VIGL Vigil Neuroscience, Inc.
3.9600
-0.75%
VRCA Verrica Pharmaceuticals Inc.
1.6000
+9.59%
MIST Milestone Pharmaceuticals Inc.
1.4900
+1.36%
IKT Inhibikase Therapeutics, Inc.
2.1300
-9.36%
SWTX SpringWorks Therapeutics, Inc.
30.97
+0.62%
TRVI Trevi Therapeutics, Inc.
3.1200
0.00%
ATXS Astria Therapeutics, Inc.
11.46
-2.55%
SNDX Syndax Pharmaceuticals, Inc.
19.71
-0.90%
XNCR Xencor, Inc.
21.78
+1.97%
ACRV Acrivon Therapeutics, Inc.
8.25
+4.83%